Every flu season, injectable vaccines prime the immune system to produce antibodies that circulate through the bloodstream. That strategy works, but it has a blind spot: by the time those antibodies reach the lungs, the virus may already have a head start. A growing body of research, built primarily on mouse experiments published in top-tier journals, suggests the lungs can maintain their own standing army of immune cells, one that responds faster and closer to where influenza actually attacks. The findings, which have gained momentum through studies published between 2008 and 2024, are now shaping how scientists think about the next generation of flu vaccines.
Immune sentinels that stay in the lungs
The central discovery is a population of memory B cells that, after a flu infection, take up long-term residence directly in lung tissue rather than recirculating through the blood. These lung-resident memory B cells (often called BRM cells in the scientific literature) behave differently from the memory B cells generated by a standard flu shot.
A 2019 study published in Nature Immunology established that BRM cells are phenotypically and functionally distinct from their circulating counterparts. Critically, the researchers found that forming these cells required direct antigen encounter in the airways. In plain terms, the virus had to reach the lungs to trigger their creation; an injection in the arm did not reliably do the same job.
Earlier work, published in PNAS in 2008, had already shown that this lung B-cell population persists for months after an initial influenza infection. When the mice were re-exposed to the virus, the resident cells rapidly differentiated into plasma cells that churned out virus-neutralizing antibodies on-site. The speed advantage is significant: instead of waiting for circulating antibodies to travel from distant tissues, the lung-resident cells were already in position and ready to fire.
A local support network inside the airways
These B cells do not work in isolation. A 2021 study in Science Immunology identified a complementary population of long-lived CD4+ T cells, dubbed “T resident helper” (TRH) cells, that also settle in lung tissue after infection. The TRH cells localize within structures called inducible bronchus-associated lymphoid tissue (iBALT), essentially small immune outposts that form in the lungs after infection or inflammation.
Together, BRM and TRH cells appear to create an organized local immune architecture: the helper T cells sustain and guide the B cells, while the B cells produce antibodies and may also coordinate broader immune responses. A conference abstract published in The Journal of Immunology found that when researchers selectively knocked out the ability of lung B cells to present antigen to T cells, the CD4 T-cell recall response during reinfection was altered. That preliminary finding hints that lung-resident B cells play a role beyond antibody production, acting as local coordinators of immune defense.
The human evidence gap
The strongest caveat is that nearly all of this evidence comes from mouse models. No published study has directly confirmed, through human lung biopsies or similar tissue sampling, that long-lived BRM cells persist and function the same way after natural influenza infection in people. Human vaccine studies that analyze peripheral blood offer indirect clues, but blood-based assays capture only part of the immune landscape and cannot measure what is happening inside lung tissue with the same precision.
A comparative study published in npj Vaccines examined immune responses across licensed influenza vaccine platforms, including standard inactivated shots, recombinant formulations, and the nasal spray vaccine FluMist. The researchers found that each platform produced measurably different memory B-cell profiles, supporting the idea that delivery route matters for shaping mucosal immunity. But even that study relied on blood-based measurements and stopped short of directly assessing lung-resident cell formation.
Other open questions remain. How broadly protective are these cells against different influenza strains? Mouse data suggest some BRM cells recognize conserved viral regions and may contribute to cross-strain defense, but durability and breadth in humans are unknown. Longitudinal studies tracking lung B-cell dynamics across repeated flu seasons or serial vaccinations have not been conducted. And no primate or human data have established a direct causal link between lung-resident B cells and prevention of severe reinfection.
Why delivery route matters for vaccine design
For the roughly 140,000 to 710,000 people hospitalized with flu in the United States each year, according to CDC estimates, the practical question is whether vaccines could be designed to seed this local immune network. Current injectable flu vaccines are engineered to generate circulating antibodies, and they do that effectively. What they appear less able to do, based on the animal data, is establish the tissue-resident memory that responds fastest at the point of viral entry.
Nasal vaccines deliver antigen directly to mucosal surfaces and are the most plausible existing platform for engaging this local pathway. The COVID-19 pandemic intensified interest in mucosal vaccine strategies for similar reasons: researchers observed that systemic immunity from injected vaccines did not always prevent upper-airway infection, even when it reduced severe disease. That parallel has added urgency to the question of whether airway-targeted flu vaccines could outperform traditional shots by activating resident immune cells in the lungs.
Still, no controlled human trial has directly measured lung-resident B-cell formation after any flu vaccination. The gap between demonstrating these cells in mice and proving they can be reliably generated in people through vaccination remains substantial.
What this means for the next wave of research
The collective evidence, spanning more than 15 years of published work, builds a compelling mechanistic case: the lungs maintain an immune memory compartment that is structurally and functionally distinct from systemic immunity. In mice, that compartment includes resident B cells capable of rapidly becoming antibody-secreting factories, helper T cells that sustain and direct those responses, and iBALT structures that serve as local coordination hubs.
As of May 2026, the field treats these findings as a strong biological rationale rather than a clinical directive. The data explain why mucosal and tissue-resident responses could matter for better flu protection and outline how they might be engaged, but they do not yet justify changing vaccination recommendations for the public.
What they do provide is a clear roadmap. The next steps include carefully designed human trials with lung-tissue sampling, improved imaging techniques to visualize resident immune cells in living patients, and vaccine candidates built specifically to test whether local immune memory in the airways can be safely and durably enhanced. If those studies confirm what the mouse work strongly suggests, the way we vaccinate against influenza could look fundamentally different within a decade.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
